MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-13-2025
VolitionRx Limited General and Administrative Expenses 2011-2026 | VNRX
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses VolitionRx Limited
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.49 M | 10.4 M | 10.2 M | 11.7 M | 5.47 M | 4.52 M | 5.78 M | 5.36 M | 5.43 M | 3.9 M | 1.91 M | 1.72 M | 1.3 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 11.7 M | 1.3 M | 5.85 M |
Quarterly General and Administrative Expenses VolitionRx Limited
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.48 M | 2.94 M | 2.24 M | - | 1.82 M | 2.28 M | 2.25 M | - | 2.6 M | 2.64 M | 2.58 M | - | 2.76 M | 3.09 M | 2.6 M | - | 3.14 M | 2.43 M | 1.81 M | - | 1.08 M | 1.51 M | 1.7 M | - | 1.35 M | 1.44 M | 1.23 M | - | 1.45 M | 1.64 M | 1.84 M | - | 1.56 M | 1.43 M | 1.4 M | - | 164 K | 166 K | 228 K | - | 141 K | 122 K | 248 K | - | 129 K | 51.8 K | 68.9 K | - | 68 K | 123 K | 51.6 K | - | 48.2 K | 149 K | 38 K | - | 54.7 K | 45.1 K | 49.9 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.14 M | 38 K | 1.27 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
46.7 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Biomerica
BMRA
|
2.98 M | $ 2.13 | -2.74 % | $ 4.89 M |  USA |
 |
Castle Biosciences
CSTL
|
200 M | $ 25.75 | 3.0 % | $ 715 M | USA |
 |
Check-Cap Ltd.
CHEK
|
9.46 M | - | - | $ 9.42 M |  Israel |
 |
Quest Diagnostics Incorporated
DGX
|
1.97 B | $ 195.6 | 0.17 % | $ 21.7 B | USA |
 |
DexCom
DXCM
|
1.29 B | $ 65.94 | -1.51 % | $ 25.7 B | USA |
 |
Brainsway Ltd.
BWAY
|
5.78 M | $ 13.71 | 0.37 % | $ 99.4 M | Israel |
|
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
21.7 M | - | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
88.1 M | $ 16.33 | 5.29 % | $ 494 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
22.3 M | - | - | $ 562 M |  Britain |
 |
Exact Sciences Corporation
EXAS
|
889 M | $ 104.91 | - | $ 19.8 B | USA |
 |
Interpace Biosciences
IDXG
|
9.49 M | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
Illumina
ILMN
|
1.09 B | $ 123.79 | -0.43 % | $ 19.7 B | USA |
 |
Aspira Women's Health
AWH
|
16.2 M | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
14.3 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
39.2 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
187 M | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
97.9 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
3.83 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
126 M | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
453 M | - | - | $ 10.7 B | USA |
 |
Charles River Laboratories International
CRL
|
743 M | $ 158.0 | 2.86 % | $ 7.83 B | USA |
 |
IQVIA Holdings
IQV
|
2 B | $ 166.96 | 0.52 % | $ 28.7 B | USA |
 |
Lantheus Holdings
LNTH
|
275 M | $ 75.73 | -0.92 % | $ 5.11 B | USA |
 |
Motus GI Holdings
MOTS
|
6.58 M | - | -34.28 % | $ 263 K | Israel |
 |
IDEXX Laboratories
IDXX
|
405 M | $ 578.51 | 0.22 % | $ 46.5 B | USA |
 |
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
192 M | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
51.9 M | $ 1.46 | 26.96 % | $ 1.86 M | USA |
 |
Medpace Holdings
MEDP
|
198 M | $ 456.93 | 0.98 % | $ 13.2 B | USA |
 |
Agilent Technologies
A
|
1.62 B | $ 112.02 | 0.65 % | $ 34.1 B | USA |
 |
ICON Public Limited Company
ICLR
|
585 M | $ 100.35 | 0.65 % | $ 8.28 B |  Irlanda |
 |
DarioHealth Corp.
DRIO
|
15.2 M | $ 7.5 | -6.13 % | $ 29.9 M | Israel |
 |
Guardant Health
GH
|
211 M | $ 84.9 | -0.33 % | $ 10.6 B | USA |
 |
Myriad Genetics
MYGN
|
257 M | $ 4.66 | 1.75 % | $ 432 M | USA |
 |
Psychemedics Corporation
PMD
|
7.19 M | - | -1.84 % | $ 15.3 M | USA |
 |
QIAGEN N.V.
QGEN
|
128 M | - | - | $ 10.6 B |  Niderland |
 |
NeoGenomics
NEO
|
273 M | $ 8.1 | 1.76 % | $ 1.04 B | USA |
 |
National Research Corporation
NRC
|
54.8 M | $ 17.51 | 1.1 % | $ 392 M | USA |
 |
Mettler-Toledo International
MTD
|
998 M | $ 1 239.07 | 2.87 % | $ 25.5 B |  Schweiz |
 |
Natera
NTRA
|
589 M | $ 200.09 | 2.46 % | $ 19.7 B | USA |
 |
CareDx, Inc
CDNA
|
108 M | $ 17.56 | 2.39 % | $ 936 M | USA |
 |
ENDRA Life Sciences
NDRA
|
7.06 M | $ 3.48 | 0.87 % | $ 1.87 M | USA |
 |
OPKO Health
OPK
|
304 M | $ 1.15 | 2.68 % | $ 798 M | USA |
 |
Celcuity
CELC
|
9.06 M | $ 106.75 | 0.67 % | $ 4.21 B | USA |
 |
Chembio Diagnostics
CEMI
|
24.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
2.22 B | $ 264.42 | 0.54 % | $ 22 B | USA |
 |
Personalis
PSNL
|
46.2 M | $ 7.61 | 4.82 % | $ 451 M | USA |
 |
DermTech
DMTK
|
43.8 M | - | -11.32 % | $ 2.94 M | USA |